Role of acquired mutations in #gout Risk factor for gout CHIP? Individuals with CHIP are more likely to developed acute episodes of gouty episodes More IL-1B in cells with somatic mutations like CHIP @rheumnow #ACR22 #yearinreview https://t.co/k3VeZuTCln

Tissue-resident memory T cells (Trm): ☝️Do not recirculate by blood or lymphatics ☝️Can drive recurrent inflammation ☝️Fixed-drug eruption is an example CD8Trm - abundant in late stage non-inflamed RA synovium #ACR22 @RheumNow #yearinreview #RheumTwitter https://t.co/LfTI0LamkN

CHIP- need to know! Somatic mutations fondly known as CHIP - not the salty ones. Clonal hematopoeisis of uncertain significance. Older Pts getting somatic mutations account for more CVS, malignancies , one change in TET2 increased gout #ACR2022 @RheumNow John Barga Yr in Review https://t.co/6bnqnkDFpL

#ACR2022 Year in Review. Dr Varga highlighted work by @GeorgeTsokos. In #lupus mice, adding CD38-i in a CD8+ T cell–targeted manner improved effector function, reversed the defects and improved viral clearance. CD38 as a target could reduce infection in SLE @rheumnow https://t.co/XlmvysjkDP

Ab0344 #ACR22 CKD2+ a/w incr HCQ levels by 149 ng/mL vs CKD1 400 mg/d dose: incr HCQ levels by 448 ng/mL vs 200 Incr body wt by 15 kg -> decr HCQ levels by 82 ng/mL Social determinants didn't effect data >750ng/mL and >1000 predicted of 75% decr flare risk @Rheumnow #ACRBest https://t.co/p21rqnO4ym

Abstr 0373 created a scoring system to predict outcomes in SpA pts w/ uveitis - Poor outcomes seen among smoking hx, females, +HLAB27, axial & peripheral involvement, high disease activity, inflammation, and b/l eye involvement https://t.co/mGAn0Eel1O @RheumNow #ACR22 https://t.co/qtJsavtG9z

New 2022 EULAR Recommendations for the Management of RA The updated '22 EULAR recommendations for the mgmt of RA were initially presented at EULAR '22, and are now in press delineating the most recent developments and perspectives in RA treatment. https://t.co/xnpOUnpgvy https://t.co/OWcRq7nZ57

Talking a lot about CAR-T these days! Upcoming @Figure1 newsletter, blog post @RheumNow, and interview w/@MaxKonigMD comping soon! I'm actually skeptical of this in SLE; are B cells really the answer? w/better targeting & dx selection, this could be game changing #ACR22 https://t.co/Z6t99ZIeMy

A group of older patients w/ multimorbidity (5+) drives higher mortality risk in RA. Crowson et al. stratification 4 clusters. Each cluster = different outcome, younger cluster w/ few comorbidities = no > mortality https://t.co/IYccicjcyy Abstr #0246 #ACR22 @Rheumnow #ACRBest https://t.co/ee9sgG3g0l

2022 has been a great year for development of novel therapies in Phase 2 RCTs in #lupus as highlighted by Dr Langford #ACR22 Year In Review. I'd add Deucravacitinib to those lists. Look forward to Phase 3 results soon @RheumNow https://t.co/yH25KFDGdd

Year in review #ACR22 IV Tocilizumab FDA approved in GCA!! Randomized trial of iv tocilizumab in PMR - 101 pts. Steroid taper was quicker. https://t.co/BQT2H8LEFk @rheumnow https://t.co/4KAYrz1IES

Very helpful slide on the different MOAs of JAK inhibitors (by Lui C et al.) shared by Dr. Langford #ACR22 @RheumNow #RheumTwitter #yearinreview https://t.co/9VIOmzNoMq